FST
Basic information
Region (hg38): 5:53480626-53487134
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
- not_specified (27 variants)
- not_provided (6 variants)
- Orofacial_cleft (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the FST gene is commonly pathogenic or not. These statistics are base on transcript: NM_000013409.3. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 1 | 2 | |||
| missense | 1 | 27 | 3 | 31 | ||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 0 | 1 | 28 | 1 | 3 |
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| FST | protein_coding | protein_coding | ENST00000256759 | 6 | 6726 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 125746 | 0 | 2 | 125748 | 0.00000795 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 2.33 | 101 | 192 | 0.527 | 0.00000995 | 2257 |
| Missense in Polyphen | 29 | 80.938 | 0.3583 | 862 | ||
| Synonymous | 0.676 | 70 | 77.6 | 0.902 | 0.00000439 | 640 |
| Loss of Function | 3.52 | 1 | 16.4 | 0.0610 | 7.76e-7 | 211 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0000292 | 0.0000292 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.00 | 0.00 |
| Finnish | 0.00 | 0.00 |
| European (Non-Finnish) | 0.00000879 | 0.00000879 |
| Middle Eastern | 0.00 | 0.00 |
| South Asian | 0.00 | 0.00 |
| Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Binds directly to activin and functions as an activin antagonist. Specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH).;
- Pathway
- TGF-beta signaling pathway - Homo sapiens (human);Hair Follicle Development- Induction (Part 1 of 3);Differentiation Pathway;TGF-beta Receptor Signaling;Signal Transduction;Antagonism of Activin by Follistatin;Signaling by Activin;BMP receptor signaling;Signaling by TGF-beta family members
(Consensus)
Recessive Scores
- pRec
- 0.486
Intolerance Scores
- loftool
- rvis_EVS
- 0.59
- rvis_percentile_EVS
- 82.45
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.978
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Zebrafish Information Network
- Gene name
- fsta
- Affected structure
- ceratobranchial cartilage
- Phenotype tag
- abnormal
- Phenotype quality
- hyperplastic
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;hematopoietic progenitor cell differentiation;negative regulation of activin receptor signaling pathway;positive regulation of hair follicle development
- Cellular component
- extracellular region
- Molecular function
- protein binding;activin receptor antagonist activity;heparan sulfate proteoglycan binding;activin binding